Physiologically Based Pharmacokinetic Modeling in Pediatric Oncology Drug Development.

@article{Rioux2016PhysiologicallyBP,
  title={Physiologically Based Pharmacokinetic Modeling in Pediatric Oncology Drug Development.},
  author={Nathalie Rioux and Nigel J. Waters},
  journal={Drug metabolism and disposition: the biological fate of chemicals},
  year={2016},
  volume={44 7},
  pages={934-43}
}
Childhood cancer represents more than 100 rare and ultra-rare diseases, with an estimated 12,400 new cases diagnosed each year in the United States. As such, this much smaller patient population has led to pediatric oncology drug development lagging behind that for adult cancers. Developing drugs for pediatric malignancies also brings with it a number of unique trial design considerations, including flexible enrollment approaches, age-appropriate formulation, acceptable sampling schedules, and… CONTINUE READING